Answers are grounded in this paper and cite their sources.
Diabetic foot ulcers (DFU) represent a global health crisis characterized by chronic inflammation and a failure to transition into the proliferative phase of wound healing. This delay is mostly caused by the abnormal overexpression of matrix metalloproteinase-9 (MMP-9), leading to indiscriminate destruction of the extracellular matrix (ECM) and essential growth factors. Conventional orthosteric inhibitors often fail due to lack of specificity and dose-limiting toxicities. This study aims to identify potential allosteric inhibitors of MMP-9 derived from Ocimum sanctum using a systemic computational framework. We employed an integrated approach combining GC–MS profiling and database mining of O. sanctum phytocompounds with transcriptomic analysis of the GSE199939 dataset. Network pharmacology was used to identify hub genes and shared targets between O. sanctum and DFU. High-precision molecular docking and 100 ns multivariate molecular dynamics (MD) simulations including RMSD, RMSF, radius of gyration (Rg), and SASA were performed to evaluate the stability of the phytocompound binding at the allosteric hemopexin-like (PEX) domain of MMP-9. Binding free energies were quantified using MM/GBSA calculations. GC–MS and database mining collectively identified 19 lead bioactive compounds with favourable ADME/drug-likeness profiles, including retinal and eugenol. Transcriptomic integration revealed 11,570 DFU-associated genes, with 52 common targets shared with O. sanctum . MMP-9 was identified as a critical structural hub (degree = 29) within the interactome, closely linked to inflammatory nodes like STAT3 and BCL2. MD simulations and FEL analysis confirmed that O. sanctum bioactives establish stable and energetically favourable interactions within the MMP-9 allosteric PEX domain. This study highlights the potential of the O. sanctum -derived phytocompounds as selective allosteric modulators of MMP-9, offering a focused, multi-target, multi-pathway approach to restore the wound microenvironment and presenting a cost-effective and safe therapeutic solution for chronic diabetic wound management.
No takes yet. Share an insight, caveat, or question.
Hemal et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: